Orum's New Preclinical Data at AACR 2026 on ORM-1153 Highlights Broad Activity in AML and the Potential for Improved Efficacy ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

Precision Biologics, Inc. announces a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing truncated core 1 O-glycans will be presented ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...

Know AML will mark AML World Awareness Day on Tuesday April 21, 2026, uniting patients, caregivers, societies, and the wider community to raise awareness of acute myeloid leukemia (AML). Many people ...

Study from Japan shows near-tripling over 30-year period ...

Delta-Fly Pharma Inc. is pressing ahead with discussions with the FDA for its lead acute myeloid leukemia (AML) candidate, radgocitabine (DFP-10917), despite a phase III miss on its primary endpoint, ...

The annual incidence of treatment-related acute myeloid leukemia has increased, in addition to an increase in the distribution of primary cancers.

Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software-based test delivers ...

Macrophages, much like Alice of “Alice in Wonderland,” recognize and consume tumor cells that display “eat me” surface markers. However, tumor cells can evade detection by macrophages if they ...

Serial post-transplant chimerism assessment provided more reliable prognostic insight than a single early measurement.